Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: Five illustrative case reports

Cancer Investigation

Volumn 30, Issue 10, 2012, Pages 712-720

  Wilgenhof, Sofie ^a   Four, Stephanie Du ^a   Everaert, Hendrik ^a   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CETIRIZINE; DACARBAZINE; GAMMA INTERFERON; IPILIMUMAB; LOPERAMIDE; MELPHALAN; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL DECISION MAKING; COMPASSIONATE USE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LICENCE; LIMB PERFUSION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXILLA SINUS CANCER; MELANOMA; MELANOMA METASTASIS; METASTATIC MELANOMA; MUSCLE METASTASIS; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RADIOFREQUENCY ABLATION; SKIN METASTASIS; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; EUROPE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SALVAGE THERAPY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84870706167     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.727934     Document Type: Article

References (30)

1. Margolin KA, Di Giacomo AM, Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol October 2010;37(5): 468-472.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb́e C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med August 2010;363(8): 711-723.
3. Robert C, Hodi FS, O'Day SJ, Peschel C, Ottensmeier CH, Trefzer U, Lorigan P, Messina M, Ibrahim R, Schadendorf D. Reinduction with ipilimumab, gp100 peptide vaccine, or a combination of both in a phase III study of previously-treated patients with advanced melanoma: update of clinical characteristics of patients. Ann Oncol 2010;21(viii403): 1330.
4. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol August 2010;21(8): 1712-1717.
5. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res September 1, 2009;15(17): 5591-5598.
6. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Jr., Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbe C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol February 2010;11(2): 155-164.
7. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs Junuary 2011;29(3): 489-498.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. January 2009;45(2): 228-247.
9. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P.Measuring response in solid tumors: unidimensional versus bidimensional measurement. JNatl Cancer Inst. March 17, 1999;91(6): 523-528.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. January 1, 1981;47(1): 207-214.
11. TherasseP, ArbuckSG,EisenhauerEA,Wanders J,KaplanRS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, ChristianMC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst February 2, 2000;92(3): 205-216.
12. Weber J. Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother May 2009;58(5): 823-830.
13. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebb́e C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res December 2009;15(23): 7412-7420.
14. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer April 1, 2010;116(7): 1767-1775.
15. Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother April 2011;60(4): 467-477.
16. Wilgenhof S, Seghers AC, Du Four S, Lienard D, Salmon I, Del Marmol V, Neyns B. Single-center experience with ipilimumab in patients with pretreated advanced melanoma. ASCO Meeting Abstracts May 30, 2012;30(15 suppl): e19026.
17. Decoster L,Neyns B, Vande Broek I, Anckaert E, De Clerck D, De Mey J,Majois F, Baurain J, Denys H, De Greve J. Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers. ASCO Meeting Abstracts June 14, 2010;28(15 suppl): 8518.
18. Du Four S, Wilgenhof S, Duerinck J, Michotte A, Binst AV, RidderMD,Neyns B. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer June 22, 2012.
19. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol November 15, 2000;18(22): 3782-3793.
20. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Jr., Morton DL, Ross MI, Sober AJ, Sondak VK. Final Version of 2009 AJCCMelanoma Staging and Classification. J Clin Oncol November 2009.;27: 6199-6206.
21. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer April 13, 2010;102(8): 1213-1218.
22. Gupta G, Robertson AG, MacKie RM. Cerebralmetastases of cutaneous melanoma. Br J Cancer 1997;76(2): 256-259.
23. Lasithiotakis K, LeiterU,Meier F, Eigentler T,Metzler G,Moehrle M, Breuninger H, Garbe C. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer April 15, 2008;112(8): 1795-1804.
24. Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist October 2009;14(10): 995-1002.
25. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, MacRae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA February 2008;105(8): 3005-3010.
26. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res December 1, 2009;15(23): 7116-7118.
27. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res July 1, 2009;69(13): 5383-5391.
28. Wang E, Panelli MC, Marincola FM. Understanding the response to immunotherapy in humans. Springer Semin Immunopathol June 2005;27(1): 105-117.
29. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget September 2011;2(9): 684-694.
30. Chang GY, Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, Lee PP. Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med 2011;9(1): 122-131.